Clinical trial
Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients…
NCT00006105 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00006105 |
|---|---|
| Title | Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer |
| Official title | Phase II Trial of Adjuvant Gemcitabine Plus Cisplatin With Amifostine Cytoprotection in Patients With Locally Advanced Bladder Cancer |
| Lead sponsor | University of Chicago, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ |
| Intervention type | Drug, Procedure |
| Interventions | amifostine trihydrate, cisplatin, gemcitabine hydrochloride, adjuvant therapy |
| Enrollment | 37 |
| Start date | Jun 1, 2000 |
| Primary completion | Nov 1, 2004 |
| Completion | Sep 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: